Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 672-684
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.672
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.672
Figure 2 Comparison of viral negativity rates between patients ≥ 75-years-old and < 75-years-old during treatment.
Rapid virological response rates of patients ≥ 75-years-old and < 75-years-old are 84% and 89%, respectively. Although rapid virological response rates tend to be higher in patients ≥ 75-years-old than in patients < 75-years-old, the difference is not significant (P = 0.266). End-of-treatment response rates for patients ≥ 75-years-old and < 75-years-old are 99% and 100%, respectively. No significant difference is seen between groups (P = 1.000).
- Citation: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/672.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.672